Skip to content
Screener

Rigel Pharmaceuticals RIGL Q2 2026 earnings

Reported August 4, 2026 · After market close

Revenue$78.7MBeat by $23.4M
EPS$0.88Beat by $0.79
Revenue estimate$55.3M
EPS estimate$0.09
“Rigel delivered a strong second quarter, highlighted by record net product sales, continued profitability and the in-license of VEPPANU, the first and only FDA-approved PROTAC for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. We expect VEPPANU to be commercially available later this month, further expanding our commercial business in hematology and oncology. We are also advancing the development of R289 in our ongoing Phase 1b study in patients with R/R lower-risk MDS, and remain on track to complete enrollment in the dose expansion phase of the study, select a recommended Phase 2 dose in the second half of 2026 and share preliminary data by year end.”
Raul Rodriguez

Next report

Nov 5, 2026 (In 3 days)
Revenue estimate$80.1M
EPS estimate$0.92

Financials

Q2 2026

Income statement

See full
Revenue$78.7M-22.6%
Gross profit$70.2M-27.8%
Operating income$23.6M-61.4%
Net income$17.3M-71.0%
EPS (diluted)$0.88-73.2%

Balance sheet

See full
Cash & equivalents$60.9M+13.9%
Total debt$40.7M+3,207%
Total equity$425.4M+419%
Total assets$521.1M+152%

Cash flow

See full
Operating cash flow$30.7M+0.4%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$961.08M+69.4%
Enterprise value$940.92M+81.0%
P/E3×-2.0×
P/S3.5×+1.5×

Profitability

See full
Gross margin91.4%-0.1pp
Operating margin31.5%-7.6pp
Net margin116.3%+79.8pp

Returns & leverage

See full
Return on equity126.9%—
Debt / equity0.1×+0.1×
Current ratio1.9×-0.1×

Segments

By product

See full
Gross product sales$88.5M+11.0%
Delivery of drug supplies, royalties and others$7.7M+179%
Development Milestones$4.0M—
Release of cost share liability-—
Discounts and allowances-$21.4M-3.4%

By segment

See full
Single reportable segment$78.7M—

FAQ

When did Rigel Pharmaceuticals report Q2 2026 earnings?
Rigel Pharmaceuticals (RIGL) reported Q2 2026 earnings on August 4, 2026 after market close.
What were Rigel Pharmaceuticals's Q2 2026 revenue and EPS?
Rigel Pharmaceuticals reported revenue of $78.7M and eps of $0.88 for Q2 2026.
Did Rigel Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $55.3M by $23.4M. EPS beat the consensus estimate of $0.09 by $0.79.
How did Rigel Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 22.6% from $101.7M a year earlier and eps declined 73.2% from $3.28.
Where can I find Rigel Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001034842-26-000053) and the 10-Q periodic report (0001034842-26-000052) directly on SEC EDGAR. The filing index links above go to sec.gov.